Orthocell (ASX:OCC) halted trading of its stocks on the Australian Securities Exchange yesterday, according to a Kalkine Media report. The trading stop came on the heels of a new equity raise for the company, which was launched through stockbroker Bell Potter Securities, according to a separate report on The Australian Financial Review. The Australian company is […]
Orthocell wins CE Mark for CelGro device
Orthocell (ASX:OCC) said today that its CelGro collagen medical device won CE Mark approval for a range of dental bone and soft tissue regeneration procedures. The company said it’s in talks with the strategic commercial partners to distribute its product throughout Europe and other key regions. Orthocell is also reportedly holding discussions with key opinion leaders […]
7 medtech stories we missed this week: Oct. 13, 2017
From Orthocell’s distribution deal to CorNeat unveiling its artificial cornea, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. OrthoCell inks Australian distro deal Orthocell announced in an Oct. 10 press release that it has signed a distribution deal with Surgical Specialities. The deal will make Surgical Specialities the […]
Orthocell touts CelGro nerve regeneration study
Orthocell (ASX:OCC) touted interim data today from an ongoing clinical study of its CelGro collagen soft tissue repair device for peripheral nerve regeneration. Researchers are evaluating the safety, tolerability and effectiveness of CelGro in surgery with patients who have suffered injury to 1 or more peripheral nerves in the hand and upper limb. The company said that […]
Orthocell, J&J’s DePuy Synthes ink R&D deal for stem cell treatment
Orthocell (ASX:OCC) said today that it landed a research collaboration deal with Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes for its Ortho-ATI stem cell regenerative therapy. The 2 groups are planning a collaborative study for the 1st quarter in 2017, led by Allan Wang from the University of Western Australia. In previous studies, Ortho-ATI has proven […]
Orthocell wins ethics nod for CelGro trial in peripheral nerve regeneration
Orthocell (ASX:OCC) said today that it won ethics approval for a human study evaluating its CelGro collagen soft tissue repair device for peripheral nerve regeneration. The study is slated to enroll 20 patients at St. John of God Hospital at the end of the calendar year. Researchers will evaluate the safety, tolerability, and effectiveness of CelGro […]
